Generic Name and Formulations:
Methenamine hippurate 1g; tabs; contains tartrazine.
Indications for HIPREX:
Prophylaxis and suppression of recurrent UTIs.
1g twice daily.
<6yrs: not recommended. ≥6yrs: 0.5–1g twice daily.
Renal or severe hepatic insufficiency. Severe dehydration.
Maintain acid urine. Monitor therapy and liver function with repeated urine cultures. Aspirin allergy. Elderly. Pregnancy.
Sulfonamides precipitate with formaldehyde in urine; avoid concomitant use.
Nausea, dysuria, rash, bladder irritation, albuminuria, hematuria, elevated transaminases.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC